As regulation of CD8 T cell homeostasis is incompletely understood, we investigated the expression profile of the vasoactive intestinal peptide (VIP) receptors, VPAC1 and VPAC2, on CD8 T cells throughout an in vivo immune response. Herein, we show that adoptively transferred CD8 T cells responding to a Listeria monocytogenes infection significantly downregulated, functionally active VPAC1 protein expression during primary and secondary expansion. VPAC1 mRNA expression was restored during contraction and regained naïve levels in primary, but remained low during secondary, memory generation. VIP co-administration with primary infection suppressed CD8 T cell expansion (≈50%). VPAC2 was not detected at any time points throughout primary and secondary infections. Collectively, our data demonstrate that functionally active VPAC1 is dynamically downregulated to render expanding CD8 T cells unresponsive to VIP.
Introduction
Vasoactive Intestinal Peptide (VIP) is delivered by the peripheral nervous system to primary and secondary immune organs (Bellinger et al., 1996; Said and Mutt, 1970) . Innate and adaptive immune cells express two G-protein coupled receptors, vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide receptor 1 (VPAC1) and VPAC2 (Delgado et al., 2004; Dickson and Finlayson, 2009; Smalley et al., 2009) , allowing these cells to respond to the VIP ligand. Originally classified as a vasoactive peptide from the gut (Said, 1974) , VIP has been re-categorized as an immunosuppressive neuropeptide (reviewed in Delgado et al., 2004) . VIP is a neurotransmitter and mitogenic factor for neurons in the brain (Pincus et al., 1990) , but is an anti-inflammatory mediator within the immune system (Bellinger et al., 1997; Ottaway and Greenberg, 1984; Xin et al., 1994) . In addition to VIP + nerves, other sources of VIP are thymocytes and activated Th 2 CD4 T cells (Delgado et al., 1999a; Vassiliou et al., 2001 ). Distinguishing whether VPAC1 or VPAC2 is responsible for VIP's effects is complicated due to the significant changes in their expression patterns depending on T cell activation status. For example, we have demonstrated that activated T cells downregulate VPAC1 mRNA expression through a Src kinase/ZAP70/JNK mediated mechanism (Vomhof-DeKrey and Dorsam, 2008; Vomhof-DeKrey et al., 2008) . Regarding VPAC2, in vitro studies have shown that its mRNA expression is inducible upon T cell activation (Delgado et al., 1996; Voice et al., 2001) . These observations were supported in vivo by Metwali et al., where they showed that schistosome infected mice had VPAC2
+ T cells present in granulomas, but splenic T cells were et al., 2000) . However, several other groups have failed to demonstrate VPAC2 upregulation by in vitro activation conditions (Metwali et al., 1996; Qian et al., 2001) . Collectively, these discrepancies emphasize the need to study VIP receptor expression in a more physiologically relevant in vivo environment. A great deal of research over the past decade has uncovered mechanisms by which VIP, binding to either VPAC1 or VPAC2, affect CD4 T cell functions, specifically Th 2 humoral immunity (Sharma et al., 2006; Voice et al., 2004 Voice et al., , 2001 . In contrast, very little data has been collected regarding the effects of VIP on cell-mediated immunity carried out by CD8 T cells. Therefore, in this study, we mapped VPAC1 and VPAC2 levels throughout a primary and secondary Listeria monocytogenes infection in the well established OT-I mouse model (Hogquist et al., 1994) . To our knowledge, this is the first report of VIP receptor measurement in an in vivo CD8 T cell immune response. Functionally active VPAC1 receptor protein and mRNA became transiently silenced during CD8 expansion, and was restored during contraction. VPAC2 mRNA, surprisingly, was not detected during Journal of Neuroimmunology 234 (2011) 40-48 
